A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase 3
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Registration Number
- NCT00047645
- Lead Sponsor
- InterMune
- Brief Summary
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Progression-free survival time 2 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie IFN-gamma 1b's therapeutic effects in idiopathic pulmonary fibrosis?
How does subcutaneous IFN-gamma 1b compare to pirfenidone in treating IPF patients unresponsive to steroids?
Which biomarkers correlate with treatment response to IFN-gamma 1b in NCT00047645 IPF trial?
What adverse events were observed in the IFN-gamma 1b arm of the InterMune phase III IPF study?
Are there combination therapies involving IFN-gamma 1b showing promise for IPF treatment?
Trial Locations
- Locations (1)
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
University of Washington Medical Center🇺🇸Seattle, Washington, United States